coiaward2010

Matchpoint - Ponatinib and Intensive Chemotherapy [UK]

Study title

Matchpoint - Ponatinib and Intensive Chemotherapy

Scientific title

Management of Transformed Chronic myeloid leukaemia: Ponatinib and intensive chemotherapy: a dose finding study (Clinicaltrialsregister.eu 2012-005629-65)

Indication and most important inclusion criteria

Male or female patients of 16 years of age or older with Ph-positive or BCR-ABL positive chronic myeloid leukemia (CML) in blast phase (BP).
Patients can be considered for inclusion in the study if they are suitable for intensive chemotherapy, have adequate kidney and liver function as well as normal pancreas function.

Short description of intervention

The aim of this trial is to find a safe and effective dose of a drug called ponatinib when used in combination with chemotherapy in patients with Chronic Myeloid Leukaemia (CML) whose disease has moved in to blast phase.

Type of study

Treatment of advanced phases

Current status

Recruiting

Study sponsor

University of Birmingham

Scientific lead / contact

Professor Mhairi Copland
University of Glasgow
Gartnavel General Hospital
Glasgow G12 0ZD

Principal investigator

Prof. Mhairi Copland
University of Glasgow
Gartnavel General Hospital
Glasgow G12 0ZD

Additional information

Study description in the EU Clinical Trials Register which is hosted by the European Medicines Agency (EMA)

Study description on the website of Cancer Research UK

Study centers / principal investigators

United Kingdom

University of Birmingham
CRCTU, Institute of Cancer and Genomic Sciences
Edgbaston, B15 2TH

Glasgow

Leeds

Liverpool

London

Nottingham